|
Herpigen Clinical Studies Learn why Herpigen is so effective, how it works and read about real case studies from patients suffering from all different forms of Herpes.
HERPIGEN In patients with herpes HSV-1, HSV-2, VZV and HPV:
In all the treated cases, HERPIGEN was effective against genital herpes, oral herpes, varicella-zoster virus and human papilloma virus. Clinical studies show it:
Clinical efficacy of HERPIGEN in the management of female herpes genitalis
-
Medical Team Doschanova A. M. Kazakh Medical State University Almaty / KAZAKHSTAN
-
Preliminary TREATMENT OF GENITAL HERPES WITH HERPIGEN AS AN ANTIVIRAL Number of patients: 22 Age: from 21 to 38 years Analysis: PCR Dosage: 6 (six) times per day Duration of treatment: 5 - 7 days Follow-up: 7 - 10 days Long-dated check-ups: monthly controls for six months
-
Results • The findings of the performed clinical trials show a high efficacy of HERPIGEN in the management of herpetic infections. 20 patients stopped complaining about itching and intense burning on the second day of the therapy, and the two remaining patients, on the third day.
• Re-examination one month after therapy with HERPIGEN revealed the total absence of herpes simplex virus in 10 patients, and six months after therapy, in another 5 females.
• No allergic reactions or side effects were reported.
-
Conclusions HERPIGEN is a preparation of high efficacy for topical use in the treatment of herpetic infections. It is practical and tolerable. Without side effects and with quick absorption.
This preparation can be recommended for wide use in the medical practice.
- Other uses
• Management of lichen shingles caused by varicella-zoster virus.
• Therapy for cytomegalovirus infection.
• Management of papilloma virus and infections caused by different types (included oncogenic ones) of the mentioned human virus.
• Therapies for vaginosis, colpitis and vaginal microflora in general, confirming its normalization.
• As a prophylactic antiviral and anti-inflammatory preparation in sexual intercourse.
Clinical trial report on the efficacy of Herpigen spray in the complex management of vaginal candidiasis in pregnant women
- Medical Team
Dr. Saparbekova A. Z. (supervision of Prof. Mamedalieva N. M.) Republican Scientific Research Centre of Maternal and Infantile Health Care Almaty / KAZAKHSTAN
October 16, 2001
- Preliminary
• Treatment of gestational vaginal candidiasis is urgent, since this type of candidiasis is twice as frequent, making up 30 - 40 % according to various authors. This disease is known to be a leading reason for severe gestational complications.
• Miscarriage and pregnancy termination incidence increases by 1.5 times; foetal and neonatal infection by 2.4 times. Therefore, timely diagnosis and management of vaginal candidiasis is especially urgent in pregnancy. Said management is complicated by the need of excluding negative effects of the preparation on the foetus.
• The efficacy of Herpigen Spray in these complex treatments of gestational vaginal candidiasis was clinically tested at the Republican Scientific Research Centre of Maternal and Infantile Health Care.
- Properties of Glycyrrhizinic Acid
• Glycyrrhizinic acid - which is contained in Herpigen - is an active agent with marked antiviral, anti-inflammatory, antipruritic, interferonogenic and immunomodulating effects.
• Glycyrrhizinic acid induces the formation of interferon, inhibits the activity of phospholipase A and the formation of prostaglandin E2 and stimulates the mechanisms of phagocytosis. The anti-inflammatory activity of glycyrrhizinic acid goes with the stimulating effect on humoral and cellular factors of immunity. The antibacterial effect of glycyrrhizinic acid was observed on the flora that conditions pathogeneity. It inhibits lipid peroxidation by binding free radicals and toxic oxidation products.
• Glycyrrhizinic acid contributes as well to the normalization of the vaginal microflora.
-
Conclusions Herpigen Spray can be recommended for local immunostimulation in the complex management of gestational vaginal infections.
Efficacy of Herpigen in the complex treatment of women with bacterial vaginosis.
-
Medical Team Abidov A. M., Faizieva G. B., Turdyeva E. Sh., Ybaidullaev Z. Kh. and Razykov A. A. Scientific Research Institute of Dermatology and Venerology MINISTRY OF PUBLIC HEALTH Republic of Uzbekistan
- Preliminary
• Bacterial vaginosis is a disease caused by an imbalance in the vaginal microflora, characterized by the increase of anaerobes and the decrease of lactobacilli.
• Bacterial vaginosis presents considerable difficulties to treatment. The products normally used are inefficient for the reduction of the recurrence rate.
• Herpigen Spray contains glycyrrhizinic acid activated by physical-chemical methods as the main active agent.
Number of patients: 16 women Age: from 19 to 25 years Duration of disease: from 3 months to 2 years Dosage: 3 - 4 times per day for 7 - 10 days
-
Conclusions
• The preparation Herpigen is practical, tolerable and does not cause side effects.
• It responded with efficacy in the complex treatment of bacterial vaginosis and can be recommended for its therapy.
Glycyrrhizinic acid (Herpigen) as an Additional Topical Treatment of Mucous Lesions in PEMPHIGUS.
-
Medical Team Svecová D., Zelenková H. Dept. of Dermatovenerology, Faculty of Medicine, Comenius University, Bratislava / SLOVAK REPUBLIC 1DOST Dept. of Dermatovenerology. Svidnik / SLOVAK REPUBLIC
-
Background The treatment of pemphigus vulgaris involves the use of systemic immunosuppressive agents. Topical treatment is only additional treatment, but it is important because of the possibility to modify the decrease of immunosuppressive drugs.
-
Objectives Glycyirrhiza glabra (licorice) is well-known and used in traditional medicine. Glycyrrhizinic acid is an effective substance and it has been proposed as an antiviral agent. Because of the anti-inflammatory and immunomodulatory effects, we used it as an additional topical treatment in patients with pemphigus to support the healing of the disease.
-
Methods Fourteen subjects suffering from mucous lesions of pemphigus (11 females, 3 males, average age 46.07 years) were treated with the topical administration of glycirrhizinic acid. They received treatment 2 - 3 times per day. All subjects were under oral administration of immunosuppressive agents.
-
Results The treatment was administered for 9 – 28 days. In 7 subjects, the lesions were completely healed (50%); in 4 subjects, there was a considerable clinical improvement (28.57%) and in 3 subjects, there was a clinical improvement (21.42%). The treatment was well tolerated by all subjects and there were no adverse effects.
-
Conclusion
This study showed a new additional topical treatment for pemphigus vulgaris.
Glycyrrhizinic acid, with its to the anti-inflammatory and immunomodulatory effects, improves the mucous lesions and reams out the possibility of the topical treatment of bullous disorders.
The use of preparations containing Glycyrhizinic Acid (Herpigen) in the dermatological practice.
-
Medical Team Hana Zelenková Dept. of Dermatovenerology, Svidnik / SLOVAK REPUBLIC Alena Nejdková Privat dermatovenerology outpatient department, Îilina / SLOVAK REPUBLIC Eva Skutilová Privat dermatovenerology outpatient department, Podunajské Biskupice / SLOVAK REPUBLIC Milan Urbáni Dept. of Dermatology, Faculty Hospital, Banská Bystrica / SLOVAK REPUBLIC Danka Svecová Dept. of Dermatology, Faculty Hospital, Bratislava / SLOVAK REPUBLIC Jirina Cabalová, Privat dermatovenerology outpatient department, Praha / SLOVAK REPUBLIC SLOVAK REPUBLIC
Glycyrrhizinic acid interacts with virus structures (proteins), producing different effects that depend on the affected viral stage: • Inactivation of free extracellular virus particles. • Prevention of intracellular uncoating of infecting particles. • Impairment of the assembling ability of structural virus components. • The anti-inflammatory effect of glycyrrrhizinic acid (GL) has been well known already in the traditional Chinese medicine. • The first studies on the effects of GL were performed in 1979 - Doll et al., Pompei, Flore et al. • The most frequent and most extensive studies were performed by Japanese authors. The development of the preparation Herpigen was based on the evaluation of latest current results of scientific research. The preparation developed according to this knowledge fulfils the attributes of absolute safety and maximum efficacy. The preparation has been applied during a multicenter study in 55 patients (herpes simplex, herpes genitalis, herpes zoster, condylomata accuminata, verucae vulgares pemphigus vulgaris, Morbus Hailey-Hailey).
- Conclusions
The therapeutic effect of the preparation was very good. Undesirable effects were observed only exceptionally.
The preparation may be administered also during pregnancy. Numerous clinical studies with Herpigen emonstrated its effectiveness in more than 90 % of the cases. The preparation is highly effective in the treatment of initial and recurrent viral infections. Therapeutically interesting is also its application for the treatment of bullous dermatoses.
Open controlled prospective multicenter study on the effectiveness, clinical safety and local tolerance of the repeated administration (T.I.D.) of activated glycyrrhizinic acid (Herpigen) in local sprayings over a period of 5 days to patients suffering from genital herpes.
|